Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 2—February 2018

Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection

Tim R.H. ReadComments to Author , Jørgen S. Jensen, Christopher K. Fairley, Mieken Grant, Jennifer A. Danielewski, Jenny Su, Gerald L. Murray, Eric P.F. Chow, Karen Worthington, Suzanne M. Garland, Sepehr N. Tabrizi, and Catriona S. Bradshaw
Author affiliations: Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia (T.R.H. Read, C.K. Fairley, M. Grant, E.P.F. Chow, K. Worthington, C.S. Bradshaw); Monash University, Melbourne, Victoria, Australia (T.R.H. Read, C.K. Fairley, G.L. Murray, E.P.F. Chow, C.S. Bradshaw); Statens Serum Institut, Copenhagen, Denmark (J.S. Jensen); Murdoch Children’s Research Institute, Parkville, Victoria, Australia (J.A. Danielewski, J. Su, G.L. Murray, S.M. Garland, S.N. Tabrizi); Royal Women’s Hospital, Parkville (J.A. Danielewski, J. Su, G.L. Murray, S.M. Garland, S.N. Tabrizi); University of Melbourne, Parkville (S.M. Garland, S.N. Tabrizi, C.S. Bradshaw)

Main Article

Table 2

Mycoplasma genitalium infections among 114 patients cured after 10 days of pristinamycin treatment, Melbourne Sexual Health Centre, Melbourne, Victoria, Australia, 2012–2016

Subgroup Pristinamycin failure, no. (%) Cured, no. (%, 95% CI) p value*
29 (25)
85 (75, 66–82)

Dosage regimen
Pristinamycin 2 g/d 2 (22) 7 (78, 40–97) 0.91
Pristinamycin 3 g with doxycycline 200 mg/d 14 (26) 40 (74, 60–85)
Pristinamycin 4 g/d
13 (25)
38 (75, 60–86)
Site of infection
Urethral infection, M 22 (29) 55 (71, 60–81) 0.20
Anorectal infection
4 (14)
24 (86, 67–96)
Patient sex
F 3 (27) 8 (73, 39–94) 1.0
26 (25)
77 (75, 65–83)
Patient signs/symptoms
Symptomatic 28 (29) 70 (71, 61–80) 0.07
Asymptomatic 1 (6) 15 (94, 70–100)

*The 3 dosage regimens were compared by nonparametric test for trend. Fisher exact test used for other variables.

Main Article

Page created: January 17, 2018
Page updated: January 17, 2018
Page reviewed: January 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.